

**Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor**

This is the peer reviewed version of the following article:

*Original:*

Spertilli Raffaelli, C., Rossetti, B., Paglicci, L., Colafigli, M., Punzi, G., Borghi, V., et al. (2018). Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(9), 2480-2484 [10.1093/jac/dky211].

*Availability:*

This version is available <http://hdl.handle.net/11365/1060031> since 2018-10-01T11:33:16Z

*Published:*

DOI:10.1093/jac/dky211

*Terms of use:*

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

**Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.**

Journal:	<i>Journal of Antimicrobial Chemotherapy</i>
Manuscript ID	JAC-2018-0210
Manuscript Type:	Brief report
Date Submitted by the Author:	06-Feb-2018
Complete List of Authors:	<p>Spertilli Raffaelli, Chiara; University of Siena, Department of Medical Biotechnologies</p> <p>Rossetti, Barbara; Azienda Ospedaliera Universitaria Senese, Infectious Diseases Unit; Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Clinic of Infectious Diseases</p> <p>Paglicci, Lorenzo; University of Siena, Department of Medical Biotechnologies</p> <p>Colafigli, Manuela; Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Clinic of Infectious Diseases</p> <p>Punzi, Grazia; Bari Hospital, Virology</p> <p>Borghi, Vanni; Modena Hospital, Infectious Diseases Unit</p> <p>Pecorari, Monica; Modena University Hospital, Microbiology and Virology Unit</p> <p>Santoro, Maria Mercedes; University of Rome "Tor Vergata", Department of Experimental Medicine and Surgery</p> <p>Penco, Giovanni; Ente Ospedaliero Ospedali Galliera, Infectious Diseases Department</p> <p>Antinori, Andrea; I.N.M.I. "L. Spallanzani", Infectious Diseases Department</p> <p>Zazzi, Maurizio; University of Siena, Department of Medical Biotechnologies</p> <p>De Luca, Andrea; University of Siena, Department of Medical Biotechnologies</p> <p>Zanelli, Giacomo; University of Siena, Department of Medical Biotechnologies</p>
Keywords:	transmitted drug resistance, HIV-1, first-line antiretroviral therapy, integrase inhibitors, protease inhibitors

**Title**

Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.

**Running head:** transmitted drug resistance and efficacy of first-line antiretroviral therapy

Spertilli Raffaelli C<sup>1</sup>, Rossetti B<sup>2,3</sup>, Paglicci L<sup>1</sup>, Colafigli M<sup>3</sup>, Punzi G<sup>4</sup>, Borghi V<sup>5</sup>, Pecorari M<sup>6</sup>, Santoro MM<sup>7</sup>, Penco G<sup>8</sup>, Antinori A<sup>9</sup>, Zazzi M<sup>1</sup>, De Luca A<sup>1</sup>, Zanelli G<sup>1</sup>.

<sup>1</sup>Department of Medical Biotechnologies, University of Siena, Siena, Italy, University Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Siena, Italy; <sup>2</sup>Infectious Diseases Unit, AOU Senese, Siena, Italy; <sup>3</sup>Clinic of Infectious Diseases, Catholic University of Sacred Heart; <sup>4</sup>Virology, Bari Hospital, Bari, Italy; <sup>5</sup>Infectious Diseases Unit, Modena Hospital, Modena, Italy; <sup>6</sup>Microbiology and Virology Unit, University Hospital, Modena, Italy; <sup>7</sup>Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy; <sup>8</sup>Infectious Diseases Department, Ente Ospedaliero Ospedali Galliera, Genoa, Italy; <sup>9</sup>Infectious Diseases Department, INMI "Lazzaro Spallanzani", Rome, Italy;

**Corresponding author:**

Spertilli Raffaelli Chiara

Department of Medical Biotechnologies,

University of Siena, Siena, Italy,

University Division of Infectious Diseases,

Hospital Department of Specialized and Internal Medicine, Siena, Italy

53100 Siena

Viale Bracci 16

Phone +39 0577586431

Fax + 39 0577586588

e-mail: [chiara.spertilli@gmail.com](mailto:chiara.spertilli@gmail.com)

**Key words:** transmitted drug resistance, HIV-1, first-line antiretroviral therapy, integrase inhibitors, protease inhibitors

## Abstract

### Objectives

The aim of this study was to examine the impact of transmitted drug resistance (TDR) on response to first-line regimens with integrase strand transfer inhibitors (INSTI) or boosted protease inhibitors (bPI).

### Methods

From an Italian observational database (ARCA) we selected HIV-1 infected drug-naïve patients starting 2 nucleoside reverse transcriptase inhibitors (NRTI) and either an INSTI or a bPI, with available pre-ART resistance genotype. The endpoint was virological failure (VF: plasma HIV-1 RNA >200 copies/ml after week 24,). WHO surveillance drug resistance mutations and the Stanford algorithm were used to classify patients into three resistance categories: no TDR (A), TDR but fully-active ART prescribed (B), TDR and at least low-level resistance to one or more prescribed drug (C).

### Results

We included 1,365 patients with a median follow-up of 96-weeks (IQR 54-110): 1,205 (88.3%) starting bPI and 160 (11.7%) INSTI. Prevalence of TDR was 6.1%, 12.5%, 0.5% and 0% for NRTI, NNRTI, bPI, and INSTI, respectively.

Cumulative Kaplan-Meier estimates for VF at 48-weeks were 11% (10.1-11.9) for the bPI- and 7.7% (5.4-10) for the INSTI-group.

In the INSTI-group, cumulative estimates for VF at 48-weeks were 6% (4-8) in resistance category A, 5% (1-10) in B and 50% (30-70) in C ( $p<0.001$ ). Resistance category C (versus A, adjusted hazard ratio, aHR 12.6, 3.2-49.8,  $p<0.001$ ) and nadir CD4 (+100 cells/ $\mu$ L, aHR 0.6, 0.4-0.9,  $p=0.03$ ) predicted VF. In the bPI-group, VF rates were not influenced by baseline resistance.

### Conclusions

Our data support the need of NRTI-resistance genotyping in patients starting an INSTI-based first-line ART.

## Introduction

Transmission of drug resistant HIV-1 is a well-known phenomenon detected in around 8% of newly diagnosed individuals in Europe, with significant differences depending on viral subtype, geographic area, risk group and migration timeline.<sup>1-3</sup> Transmitted drug resistance (TDR) is increasing in Southern and Eastern Africa, particularly to the antiretroviral class of non-nucleoside reverse transcriptase inhibitors (NNRTI), a cornerstone of recommended first-line antiretroviral therapy (ART) in these countries.<sup>4</sup> TDR may significantly influence the outcome of ART,<sup>5-7</sup> therefore drug resistance testing is recommended for the choice of the first-line regimen in resource-rich countries.<sup>8-11</sup>

The risk of virological failure was increased in patients harboring pre-treatment drug resistance to at least one of the prescribed drugs in NNRTI-based regimens, as compared with individuals without pre-treatment drug resistance, but not in patients with pre-treatment drug resistance and fully active ART.<sup>12</sup>

International panels currently recommend first-line ART regimens including integrase strand transfer inhibitors (INSTI) or boosted protease inhibitors (bPI), because of their efficacy and tolerability.<sup>9-11</sup> However, in the absence of resistance testing, some authors suggest to use bPI due to their higher genetic barrier compared with INSTI.<sup>8</sup> Indeed, the influence of TDR on the efficacy of INSTI-based first-line regimens has not yet been established, due to the exclusion of individuals carrying TDR from clinical trials and the sparse data from observational cohorts.<sup>5,6,13-16</sup>

The aim of this study was to examine the impact of TDR on response to first-line regimens in naïve patients starting INSTI-based 3-drug antiretroviral therapy. As a reference, we also analyzed the impact of TDR on the efficacy of boosted PI-based regimens.

## Methods

Protease, reverse transcriptase and integrase genotype sequences from treatment-naïve HIV-1 infected adults starting a first-line therapy including 2 nucleoside or nucleotide

reverse transcriptase inhibitors (NRTI) plus 1 INSTI or 2 NRTI plus 1 bPI from January 2008 to June 2016 were selected from the Antiviral Response Cohort Analysis (ARCA), an Italian multicenter virological and clinical database [<http://www.dbarca.net>], including cases with at least 1 plasma HIV-1 RNA value after 24 weeks of follow up. The database was approved by the local Ethics Committees and written informed consent was obtained from all patients before participation. The study was performed in accordance with the ethical guidelines of the Declaration of Helsinki (7th revision).

Plasma genotypic resistance was determined by Sanger's population sequencing using commercially available or homebrew systems. TDR was defined as the detection of at least one mutation among those included in the WHO-recommended surveillance drug resistance mutation (SDRM) list for NRTI, NNRTI, bPI<sup>17</sup> and those included in the Stanford HIVdb SDRM Worksheet for INSTI [<https://hivdb.stanford.edu/pages/SDRM.worksheet.INI.html>]. The Stanford HIVdb algorithm (version 8.4, <https://hivdb.stanford.edu>) was used to classify patients into three resistance categories:<sup>4</sup> absence of TDR mutations (resistance category A), presence of TDR mutations but use of a fully-active ART regimen (B), or presence of TDR mutations and at least low-level resistance to at least one prescribed drug (C). HIV-1 subtyping was available as automatically performed by BLAST upon sequence upload and further analyzed by phylogenetic analysis in case of <95% homology to the pure subtype reference panel.

The primary outcome was virological failure, defined as a plasma HIV-1 RNA >200 copies/mL after week 24, ignoring treatment changes. Survival analysis, using Kaplan-Meier curves, was employed to estimate the probability of virological failure. Predictors of virological failure were investigated using Cox regression models. All analyses were performed using SPSS (version 22, IBM, Armonk, NY).

## Results

A total of 1,365 patients were included, 1,205 (88.3%) treated with 2 NRTI plus 1 bPI and 160 (11.7%) treated with 2 NRTI plus 1 INSTI. Baseline patients' characteristics are shown in table 1. The main differences between the two treatment groups were a higher baseline plasma HIV-1 RNA and lower baseline and nadir CD4 cells counts in

the bPI group. Patients in the INSTI group were cared more frequently in Southern Italy and started therapy more recently. The most frequently prescribed INSTI was raltegravir (RAL) (39%), followed by dolutegravir (DTG) (35%) and elvitegravir/cobicistat (EVG/c) (26%). The most frequently used bPI was lopinavir/ritonavir (LPV/r) (41%), followed by atazanavir/ritonavir (ATV/r) (30%) and darunavir/ritonavir (DRV/r) (28%).

The overall prevalence of any TDR mutation was 18.4%, without differences between groups. NRTI, NNRTI, PI and INSTI resistance mutations were detected in 83 (6.1%), 171 (12.5%), 35 (2.6%) and 0 (0.0%) patients, respectively. While there was a similar prevalence of NRTI TDR in the two treatment groups, NNRTI TDR was more frequent in the bPI group (13.1% versus 8.1% in the INSTI group,  $p=0.043$ ), whereas PI TDR was less frequent in the PI group (2.1% versus 6.3%,  $p=0.05$ ).

During a median follow-up time of 96 weeks (IQR 54-110) virological failure occurred in 195 individuals in the PI-group and in 11 in the INSTI-group, with an estimated cumulative probability at 48 weeks of 11% (CI 95% 10.1-11.9) and 7.7% (CI 95% 5.4-10), respectively ( $p=0.01$  by log-rank test).

In the INSTI group, resistance category C showed a significantly higher estimated probability of 48-week virological failure (50%, 95% CI 30-70) versus A (6%, 95% CI 4-8) and B (5%, 1-10) ( $p<0.001$ ). By contrast, in the bPI group the estimated probability of virological failure at 48 weeks was similar in three categories: category A 11% (95% CI 10-12), B 12% (95% CI 10-14) and C 9% (95% CI 5-13) ( $p=0.390$ ) (Fig.1). In the INSTI group, but not in the PI group, resistance category C (versus A, adjusted hazard ratio, aHR 12.6, 3.2-49.8,  $p<0.001$ ) and nadir CD4 (+100 cells/ $\mu$ L higher, aHR 0.6, 0.4-0.9,  $p=0.03$ ) independently predicted virological failure. In the PI group, in a multivariable model adjusting for gender, nationality, TDF/FTC use, viral subtype, type of bPI and TDR to NRTI, independent predictors of virological failure were AZT/3TC use (aHR 2.3, CI 95% 1.4-3.9,  $p=0.002$ ), calendar year (per 1 year more recent, aHR 0.9, CI 95% 0.8-0.9,  $p=0.04$ ) and LPV/r use (versus DRV/r, aHR 1.4, CI 95% 1.0-2.0,  $p=0.03$ ).

Eleven patients, mostly (9/11) harboring viral subtype B, experienced virological failure in the INSTI group: 8 were on treatment with RAL, 2 with DTG and 1 with EVG/c. At failure, plasma HIV-1 RNA ranged between 210 and 213,200 copies/mL and higher values were detected in patients with lower baseline CD4 counts. Three of the 11 failing INSTI carried TDR to NRTI: 2 M41L and 1 M184V, while none carried resistance to INSTI. Seven patients changed antiretroviral therapy after virological failure, with 6 patients switching to a bPI-based regimen. Among those that continued the previous regimen, 3 reached virological re-suppression at the subsequent visit and 1 was lost to follow up.

178

## 179 Discussion

180

The key finding of this study is the impact of pre-treatment HIV-1 drug resistance on the risk of virological failure in patients initiating ART with 2 NRTI plus INSTI. Despite the small number of cases, the magnitude of this effect was very relevant, with a more than 10-fold higher adjusted hazard of virological failure as compared to patients without TDR. To our knowledge, this is the first report showing a significant impact of TDR to NRTI on the activity of first-line regimens with 2 NRTI plus INSTI, the current standard of care of first-line ART. Indeed, previous observational studies on the influence of TDR did not include INSTI-based regimens and clinical trials with INSTI excluded patients with TDR.<sup>1,2,5,13,18,19</sup> Interestingly, in the same group, TDR not affecting the activity of the prescribed drugs did not show any impact on virological efficacy. This finding is reassuring, suggesting that even in the presence of TDR, INSTI-based first-line regimens are effective when fully active accompanying drugs are selected based on the resistance test result.

194

The overall prevalence of TDR in this cohort was 18.4%, higher than usually reported in European cohorts, and was primarily driven by NNRTI resistance.<sup>1-3</sup> This could be explained by the fact that, detection of TDR may have advised to use high-genetic barrier bPI therapy, resulting in an overestimate of TDR in the case file. In addition, bPI-based regimens were preferentially prescribed to more challenging patients, such as those with higher baseline viral load and lower CD4 counts, possibly explaining at least in part the higher virological efficacy of INSTI-based as compared with PI-based regimens observed here. The relatively long period of observation (2008-2016) may



203 also explain some imbalance observed between the two treatment groups reflecting drug  
204 availability over time. In the PI-group, AZT/3TC and LPV/r use were associated to  
205 more frequent virological failure, suggesting a crucial role of their lower tolerability and  
206 efficacy.

207  
208 The main limitations of this study are the retrospective nature, the small number of  
209 patients treated with INSTIs and the relatively limited sample size in the INSTI  
210 treatment groups, which did not allow a sufficient power to detect differences among  
211 drugs with different genetic barrier. Future analyses including a larger and balanced  
212 INSTI group are necessary to confirm our findings and clarify whether NRTI TDR has  
213 a different impact on virological efficacy using different types of INSTI.

214  
215 In conclusion, our findings support the need of pre-treatment drug resistance testing to  
216 NRTI in order to optimize antiretroviral therapy in patients starting first-line INSTI-  
217 based regimens.

## 218 219 **Acknowledgments**

220  
221 We thank the patients sharing their data, the ARCA clinical and laboratory units and the  
222 ARCA Scientific Board. ARCA was supported by unconditional educational grants  
223 from ViiV Healthcare, Gilead Sciences, Janssen, Hologic, MSD, Bristol-Myers Squibb,  
224 Siemens Healthineers.

## 225 226 **Funding**

227 This study was conducted as part of our routine work.

## 228 229 **Transparency declarations**

230  
231 CSR, LP, GP, VB, MP, GP and GZ none to declare.  
232 BR declare consultant fees from Janssen, ViiV Healthcare, Abbvie, MSD and Gilead,  
233 all outside the submitted work.  
234 MC received speakers' honoraria and support for travel to meetings from BMS, Gilead,  
235 Merck Sharp &Dohme (MSD), ViiV Healthcare and JC.

MMS has received funds for attending symposia, speaking, organizing educational activities and participating at Scientific Board from ViiV, Janssen Cilag and Gilead. AA received fees for consultancy from Abbvie, Bristol Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck, ViiV Healthcare, and research institutional grants from Bristol Myers Squibb, Gilead Sciences, Janssen-Cilag, ViiV Healthcare. MZ grants from ViiV Healthcare e Gilead Sciences, consultancy fees from ViiV Healthcare, Gilead Sciences e Janssen-Cilag. ADL Received unrestricted research grants from ViiV, Merck and Gilead (Fellowship Program) and was a paid consultant for ViiV, Merck and Gilead and Janssen-Cilag.

245

## 246 References

247

248 1 Hofstra LM, Sauvageot N, Albert J et al. Transmission of HIV Drug Resistance and  
249 the Predicted Effect on Current First-Line Regimens in Europe. *Clin Infect Dis* 2016;  
250 62:655-663.

251

252 2 Colafigli M, Torti C, Trecarichi EM et al. Evolution of transmitted HIV-1 drug  
253 resistance in HIV-1-infected patients in Italy from 2000 to 2010. *Clin Microbiol Infect*  
254 2012; 18:E299-E304.

255

256 3 Hauser A, Hofmann A, Hanke K et al. National molecular surveillance of recently  
257 acquired HIV infections in Germany, 2013 to 2014. *Euro Surveill* 2017; 22:pii=30436.

258

259 4 Gupta RK, Gregson J, Parkin N et al. HIV-1 drug resistance before initiation or re-  
260 initiation of first-line antiretroviral therapy in low-income and middle-income countries:  
261 a systematic review and meta-regression analysis. *Lancet Infect Dis* 2017 Dec 5, pii:  
262 S1473-3099(17)30702-8.

263

264 5 Wittkop L, Gunthard HF, de Wolf F et al. Effect of transmitted drug resistance on  
265 virological and immunological response to initial combination antiretroviral therapy for  
266 HIV (EuroCoord-CHIAN joint project): a European multicohort study. *Lancet Infect*  
267 *Dis* 2011; 11:363-371.

268

- 269 **6** Di Biagio A, Rusconi S, Marzocchetti A et al. The role of baseline HIV-1 RNA, drug  
270 resistance, and regimen type as determinants of response to first-line antiretroviral  
271 therapy. *J Med Virol* 2014; 86: 1648-1655.
- 272
- 273 **7** Kantor R, Smeaton L, Vardhanabhuti S et al. Pretreatment HIV drug Resistance and  
274 HIV-1 Subtype C are independently associated with virological failure: results from the  
275 multinational PEARLS (ACTG A5175) Clinical Trial. *Clin Infect Dis* 2015; 60: 1541-  
276 1549.
- 277
- 278 **8** Linee guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione  
279 diagnostico-clinica delle persone con infezione da HIV-1.  
280 <http://www.simit.org/medias/1047-lg-hiv-2016-c17pubblicazioni2545allegato.pdf>
- 281
- 282 **9** Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and  
283 Adolescents. <https://aidsinfo.nih.gov/guidelines> on 9/9/2017
- 284
- 285 **10** Guidelines, version 9.0. European AIDS Clinical Society (EACS), October  
286 2017. <http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>.
- 287
- 288 **11** Antiretroviral drugs for treatment and prevention of HIV infection in adults 2016  
289 Recommendations of the International Antiviral-Society – USA panel.  
290 <https://jamanetwork.com/journals/jama/fullarticle/2533073>.
- 291
- 292 **12** Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug  
293 resistance on immunological, virological, and drug-resistance outcomes of first-line  
294 antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. *Lancet Infect*  
295 *Dis* 2012; 12:307-317.
- 296
- 297 **13** Clotet B, Feinberg J, van Lunzen J et al. Once-daily dolutegravir versus darunavir  
298 plus ritonavir in antiretroviral-naïve adults with HIV infection (FLAMINGO): 48 week  
299 results from the randomised open-label phase 3b study. *Lancet* 2014; 383:2222-2231.
- 300
- 301 **14** Lennox JL, Landovitz RJ, Ribaudo HJ et al. Efficacy and tolerability of 3  
302 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for

303 treatment-naïve volunteers infected with HIV-1: a randomized-controlled, equivalence  
304 trial. *Ann Intern Med* 2014; 161:461-471.

305

306 **15** Socias ME, Nosova E, Kerr T et al. Patterns of transmitted drug resistance and  
307 virological response to first-line antiretroviral treatment among HIV-positive people  
308 who use illicit drugs in a Canadian setting. *Clin Infect Dis* 2017 May 6. Doi:  
309 10.1093/cid/cix428 [Epub ahead of print].

310

311 **16** Zu Knyphausen F, Scheufele R, Kucherer C et al. First line treatment response in  
312 patients with transmitted HIV drug resistance and well defined time point of HIV  
313 infection: updates results from the German HIV-1 seroconverter study. *PLoS One* 2014;  
314 9:e95956.

315

316 **17** Bennett DE, Camacho RJ, Otelea D et al. Drug resistance mutations for surveillance  
317 of transmitted HIV-1 drug-resistance: 2009 update. *PLoS One* 2009; 4(3):e4724.

318

319 **18** Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in  
320 previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-  
321 inferiority trial. *Lancet Infect Dis* 2011 Dec;11(12):907-15.

322

323 **19** Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor  
324 based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-  
325 blind, phase 3 study. *Lancet HIV* 2016 Sep;3(9):e410-e420.

326

327

328

329

330

331

332


333

334

335

336

Fig.1 Kaplan–Meier curves showing the impact of the different pre-treatment HIV-1 drug resistance category on the virological outcome of first-line regimens based on 2 NRTI plus either a boosted PI (a) or an integrase inhibitor (b).



341

342

343

a. PI-group

b. INSTI-group

Table 1. Baseline characteristics of the patient population.

Characteristics	Overall N= 1,365	bPI group N= 1,205	INSTI group N= 160	P-value*
Male, n (%)	1006/1355 (73.7)	880/1196 (73.0)	126/159 (78.8)	0.30
Age (year), median (IQR)	40 (33-48)	40 (33-48)	40 (30- 48)	0.60
Italian born, n (%)	982/1365 (71.9)	882/1205 (73.2)	100/160 (62.5)	0.05
Risk factor, n (%):				<0.001
Heterosexual contacts	444 (32.5)	405 (33.6)	39 (24.4)	
MSM	272 (19.9)	245 (20.3)	27 (16.8)	
Injection drug users	109 (8.0)	101 (8.4)	8 (5.0)	
Other/Unknown	540 (39.6)	454 (37.7)	86 (53.8)	
Geographical area, n (%):				<0.001
Northern Italy	584 (42.8)	540 (44.8)	44 (27.5)	
Central Italy	522 (38.2)	465 (38.6)	57 (35.6)	
Southern Italy and Islands	259 (19.0)	200 (16.6)	59 (36.9)	
Calendar year of treatment start, median (IQR)	2011 (2009-2013)	2011 (2009-2012)	2015 (2014-2016)	<0.001
Time from HIV diagnosis (years), median (IQR)	0.3 (0.1-2.5)	0.3 (0.1-2.5)	0.5 (0.2-2.9)	0.60
Baseline plasma HIV-1 RNA (log <sub>10</sub> copies/mL), median (IQR)	4.9 (4.3-5.4)	4.9 (4.4-5.4)	4.7 (4-5.2)	< 0.001
Baseline CD4 cell count (cells/mm <sup>3</sup> ), median (IQR)	258.5 (103-383)	240 (96-364)	380 (198-557)	<0.001
CD4 nadir cell count (cells/mm <sup>3</sup> ), median (IQR)	230 (95-346)	222 (89-334)	323 (167-496)	<0.001
Subtype, n (%):				
B	944 (69.2)	839 (69.6)	105 (65.6)	0.30
non B	421 (30.8)	366 (30.4)	55 (34.4)	
Backbone, n (%):				
TDF/FTC	1011 (74.1)	895 (74.3)	116 (72.5)	0.63
ABC/3TC	240 (17.6)	198 (16.4)	42 (26.2)	0.002
AZT/3TC	102 (7.5)	102 (8.5)	0 (0)	<0.001
other	12 (0.9)	10 (0.8)	2 (1.3)	0.59
Anchor drug	DRV/r	339 (28.1)		

Patients with transmitted drug resistance, n (%):	LPV/r		499 (41.4)			
	ATV/r		367 (30.5)			
	RAL			63 (39.4)		
	EVG			41 (25.6)		
	DTG			56 (35.0)		
	Any class	251 (18.4)	222 (18.4)	29 (18.1)		0.514
	NRTI	83 (6.1)	74 (6.1)	9 (5.6)		0.484
	NNRTI	171 (12.5)	158 (13.1)	13 (8.1)		0.043
	PI	35 (2.6)	25 (2.1)	10 (6.3)		0.05
	INSTI	0 (0.0)	0 (0.0)	0 (0.0)		

ABC/3TC, abacavir/lamivudine; ATV/r, atazanavir/ritonavir; AZT/3TC, zidovudine/lamivudine; DRV/r, cps/mL, copies/mL; darunavir/ritonavir; DTG, dolutegravir; EVG, elvitegravir; INSTI, Integrase strand transfer inhibitors; LPV/r, lopinavir/ritonavir; MSM, man who have sex with man; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; bPI, boosted protease inhibitor; RAL, raltegravir; TDF/FTC, tenofovir/emtricitabine.